Zhejiang Hisun Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of biological and generic drugs in China. The company provide...
April 15 Midday Market Review: GEM Index Opens High and Falls, Closing Down 0.23%; Innovative Drug Concepts Rally Collectively
HISUN's revenue in 2025 is expected to be 10.55 billion yuan
Xinhua Pharmaceutical Wins NMPA Approval for New Electrolyte Injection
China's pet prescription food welcomes a breakthrough player
HISUN: Has cumulatively spent CNY 56.9915 million to repurchase 0.51% of its shares
On the morning of the second day of the National Conference in 2025: Shenghe Pharmaceutical, HISUN, and other pharmaceutical companies enter the venue